INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 426m ago
HOUSE PTR25m ago
SEC 13F25m ago
ROBINHOOD CHAIN25m ago
Public company

ACADACADIA PHARMACEUTICALS INC

CIK 0001070494

EDGAR filingsOpen in network
Disclosed transactions56
Buys / sells0 / 17
Max Insider Score51
Connections10with evidence

ACAD · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
16
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Grant or award
A—
6,815 sh
Oct 15, 2026Oct 30, 2026
traded Oct 15, 2026
+15dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    TIBER CREEK GROUPLDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    HOLLAND & KNIGHT LLPLDA Q1 2026 first quarter · Taxation · Aug 26, 2026
  • ← Insider ofevidence
    Ndu AdoraDirector · Jun 1, 2026
17
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL
$69K
3,321 sh
Oct 30, 2026
Oct 30, 2026
traded Oct 30, 2026
+0d
SEC FORM 4

Evidence

0
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
14.3K sh
Aug 6, 2026Aug 7, 2026
traded Aug 6, 2026
+1dSEC FORM 4

Evidence

0
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
5,849 sh
Aug 5, 2026Aug 7, 2026
traded Aug 5, 2026
+2dSEC FORM 4

Evidence

8
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$273K
9,292 sh
Aug 6, 2026Aug 7, 2026
traded Aug 6, 2026
+1dSEC FORM 4

Evidence

6
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$255K
14.3K sh
Aug 6, 2026Aug 7, 2026
traded Aug 6, 2026
+1dSEC FORM 4

Evidence

5
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$145K
5,000 sh
Aug 6, 2026Aug 7, 2026
traded Aug 6, 2026
+1dSEC FORM 4

Evidence

8
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$170K
5,849 sh
Aug 5, 2026Aug 7, 2026
traded Aug 5, 2026
+2dSEC FORM 4

Evidence

2
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$104K
5,849 sh
Aug 5, 2026Aug 7, 2026
traded Aug 5, 2026
+2dSEC FORM 4

Evidence

15
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$298K
11.4K sh
Jun 26, 2026Jun 29, 2026
traded Jun 26, 2026
+3dSEC FORM 4

Evidence

17
GA
Garofalo Elizabeth A.Director
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
8,107 sh
May 29, 2026Jun 1, 2026
traded May 29, 2026
+3dSEC FORM 4

Evidence

17
NA
Ndu AdoraDirector
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
8,107 sh
May 29, 2026Jun 1, 2026
traded May 29, 2026
+3dSEC FORM 4

Evidence

9
NA
Ndu AdoraDirector
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
8,107 sh
May 29, 2026Jun 1, 2026
traded May 29, 2026
+3dSEC FORM 4

Evidence

9
NA
Ndu AdoraDirector
ACADACADIA PHARMACEUTICALS INC
Grant or award
A—
16.0K sh
May 29, 2026Jun 1, 2026
traded May 29, 2026
+3dSEC FORM 4

Evidence

9
NA
Ndu AdoraDirector
ACADACADIA PHARMACEUTICALS INC
Grant or award
A—
9,311 sh
May 29, 2026Jun 1, 2026
traded May 29, 2026
+3dSEC FORM 4

Evidence

9
GA
Garofalo Elizabeth A.Director
ACADACADIA PHARMACEUTICALS INC
Grant or award
A—
16.0K sh
May 29, 2026Jun 1, 2026
traded May 29, 2026
+3dSEC FORM 4

Evidence

9
GA
Garofalo Elizabeth A.Director
ACADACADIA PHARMACEUTICALS INC
Grant or award
A—
9,311 sh
May 29, 2026Jun 1, 2026
traded May 29, 2026
+3dSEC FORM 4

Evidence

9
GA
Garofalo Elizabeth A.Director
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
8,107 sh
May 29, 2026Jun 1, 2026
traded May 29, 2026
+3dSEC FORM 4

Evidence

9
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
2,010 sh
Apr 5, 2026Apr 7, 2026
traded Apr 5, 2026
+2dSEC FORM 4

Evidence

32
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL$23K
1,030 sh
Apr 7, 2026Apr 7, 2026
traded Apr 7, 2026
+0dSEC FORM 4

Evidence

5
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
2,010 sh
Apr 5, 2026Apr 7, 2026
traded Apr 5, 2026
+2dSEC FORM 4

Evidence

5
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
5,276 sh
Apr 5, 2026Apr 7, 2026
traded Apr 5, 2026
+2dSEC FORM 4

Evidence

35
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL$60K
2,709 sh
Apr 7, 2026Apr 7, 2026
traded Apr 7, 2026
+0dSEC FORM 4

Evidence

9
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
5,276 sh
Apr 5, 2026Apr 7, 2026
traded Apr 5, 2026
+2dSEC FORM 4

Evidence

17
OC
Owen Adams CatherineDirector, Chief Executive Officer
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
23.5K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

9
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
8,138 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

39
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL$90K
4,177 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

9
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
6,178 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

35
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL$69K
3,171 sh
Mar 26, 2026Mar 26, 2026
traded Mar 26, 2026
+0dSEC FORM 4

Evidence

32
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL$804
37 sh
Mar 26, 2026Mar 26, 2026
traded Mar 26, 2026
+0dSEC FORM 4

Evidence

17
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
8,138 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

17
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
6,178 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

9
TZ
Thompson Elizabeth H.Z.EVP, Head of Research & Dev
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
6,715 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

51
TZ
Thompson Elizabeth H.Z.EVP, Head of Research & Dev
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL$74K
3,435 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

17
TZ
Thompson Elizabeth H.Z.EVP, Head of Research & Dev
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
6,715 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

21
OC
Owen Adams CatherineDirector, Chief Executive Officer
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
23.5K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

47
OC
Owen Adams CatherineDirector, Chief Executive Officer
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL$250K
11.6K sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

9
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
1,627 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

32
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL$18K
833 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

9
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
2,142 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

13
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
1,627 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

17
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
2,142 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

32
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL$24K
1,097 sh
Mar 26, 2026Mar 26, 2026
traded Mar 26, 2026
+0dSEC FORM 4

Evidence

32
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL$261
12 sh
Mar 26, 2026Mar 26, 2026
traded Mar 26, 2026
+0dSEC FORM 4

Evidence

9
GT
Garner ThomasEVP, Chief Commercial Officer
ACADACADIA PHARMACEUTICALS INC
Grant or award
A—
28.5K sh
Mar 6, 2026Mar 10, 2026
traded Mar 6, 2026
+4dSEC FORM 4

Evidence

9
GT
Garner ThomasEVP, Chief Commercial Officer
ACADACADIA PHARMACEUTICALS INC
Grant or award
A—
97.9K sh
Mar 6, 2026Mar 10, 2026
traded Mar 6, 2026
+4dSEC FORM 4

Evidence

13
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
9,913 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

17
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
9,913 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

9
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
3,966 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

9
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
3,966 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

33
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL$243K
10.3K sh
Nov 18, 2025Nov 19, 2025
traded Nov 18, 2025
+1dSEC FORM 4

Evidence

33
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Open-market sale
SELL$97K
4,084 sh
Nov 18, 2025Nov 19, 2025
traded Nov 18, 2025
+1dSEC FORM 4

Evidence

13
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
3,966 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

9
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
9,913 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

13
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
3,966 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

9
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
9,913 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Garofalo Elizabeth A.Director · Jun 1, 2026
  • ← Insider ofevidence
    Owen Adams CatherineDirector, Chief Executive Officer · Mar 26, 2026
  • ← Insider ofevidence
    Thompson Elizabeth H.Z.EVP, Head of Research & Dev · Mar 26, 2026
  • ← Insider ofevidence
    Garner ThomasEVP, Chief Commercial Officer · Mar 10, 2026
  • ← Insider ofevidence
    Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Nov 19, 2025
  • ← Insider ofevidence
    Kihara JamesPRINCIPAL ACCOUNTING OFFICER · Nov 19, 2025

    • Lobbying

    $1.30M reported · de-duplicated
    2026 Q2 $700K in-house2026 Q1 $600K in-house
    • HOLLAND & KNIGHT LLP$20K2026 Q2 · posted Aug 26, 2026 · Taxation
    • In-house report$700K2026 Q2 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid, Taxation, Trade
    • TIBER CREEK GROUP$80K2026 Q1 · posted Aug 26, 2026 · Health issues
    • In-house report$600K2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid, Taxation
    • TIBER CREEK GROUP$80K2026 Q2 · posted Aug 26, 2026 · Health issues
    • HOLLAND & KNIGHT LLP$20K2026 Q1 · posted Aug 26, 2026 · Taxation

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.